Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Februar 2018 11:38 ET | Quelle: ORPHAZYME A/S

Poster presentation at WORLDSymposium™ 2018 – arimoclomol as clinical candidate for treatment of Gaucher disease

Investor newsOrphazyme A/SNo. 02/2018 ...
29. Januar 2018 11:29 ET | Quelle: ORPHAZYME A/S

Capital increase of 11,380 shares (equivalent to approximately 0.06% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB

Company announcementOrphazyme A/SNo. 02/2018 Copenhagen, Denmark, January 29, 2018 – Orphazyme A/S, a Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage,...
24. Januar 2018 16:06 ET | Quelle: ORPHAZYME A/S

Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS

Investor newsOrphazyme A/SNo. 01/2018 ...
19. Januar 2018 02:16 ET | Quelle: ORPHAZYME A/S

Arimoclomol for NPC receives Rare Pediatric Disease Designation

Company announcementOrphazyme A/SNo. 01/2018 ...
18. Dezember 2017 07:08 ET | Quelle: ORPHAZYME A/S

Major shareholder announcement

Orphazyme A/SCompany announcementNo. 17/2017 ...
15. Dezember 2017 09:20 ET | Quelle: ORPHAZYME A/S

Orphazyme assumes sponsorship of Phase II/III sIBM trial

Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...
14. Dezember 2017 13:02 ET | Quelle: ORPHAZYME A/S

Stabilisation measures taken and end of stabilisation period

Company announcementNo. 16/2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN This announcement...